Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Investing.com -- Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities in drug …